Lawrence Deandre Patterson

US Patent:

61111104, Aug 29, 2000

Filed:

Mar 12, 1999

Appl. No.:

9/254829

Inventors:

John Brennan - Indianapolis IN
Christopher William Doecke - Indianapolis IN
Perry Clark Heath - Indianapolis IN
Lawrence Edward Patterson - Indianapolis IN
Uko Effiong Udodong - Indianapolis IN
Leland Otto Weigel - Indianapolis IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C07D22106
C07D49800

US Classification:

546110

Abstract:

A process for preparing intermediates and benzoquinolin-3-one pharmaceuticals, such pharmaceuticals are effective in treating conditions consequent on 5. alpha. -reductase.

US Patent:

49653741, Oct 23, 1990

Filed:

Dec 4, 1989

Appl. No.:

7/445139

Inventors:

Perry C. Heath - Indianapolis IN
Lawrence E. Patterson - Indianapolis IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C07D30732

US Classification:

549313

Abstract:

The present invention provides a process for preparing lactone intermediates to 2',2'-difluoronucleosides whereby reversion back to the lactone's open chain precursor is minimized and the desired erythro enantiomer can be selectively isolated from an enantiomeric mixture of erythro and threo lactones in crystalline form. Also provided is a process for producing 2'-deoxy-2',2'-difluoronucleosides in about a 1:1. alpha. /. beta. anomeric ratio, and processes for selectively isolating. beta. -2'-deoxy-2',2'-difluorocytidine, or an organic or inorganic acid addition salt thereof, from the 1:1. alpha. /. beta. mixture.

US Patent:

54342546, Jul 18, 1995

Filed:

Apr 19, 1993

Appl. No.:

8/049220

Inventors:

Perry C. Heath - Indianapolis IN
Lawrence E. Patterson - Indianapolis IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C07H 1900

US Classification:

536 2713

Abstract:

The present invention provides a process for preparing lactone intermediates to 2',2'-difluoronucleosides whereby reversion back to the lactone's open chain precursor is minimized and the desired erythro enantiomer can be selectively isolated from an enantiomeric mixture of erythro and threo lactones in crystalline form. Also provided is a process for producing 2'-deoxy-2',2'-difluoronucleosides in about a 1:1. alpha. /. beta. anomeric ratio, and processes for selectively isolating. beta. -2'-deoxy-2',2'-difluorocytidine, or an organic or inorganic acid addition salt thereof, from the 1:1. alpha. /. beta. mixture.